Affinage

SND1

Staphylococcal nuclease domain-containing protein 1 · UniProt Q7KZF4

Length
910 aa
Mass
102.0 kDa
Annotated
2026-06-10
100 papers in source corpus 41 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SND1 is a multifunctional staphylococcal-nuclease-domain protein that couples RNA metabolism, chromatin-based transcriptional co-activation, and protein turnover to drive cancer progression and tissue remodeling (PMID:28263968, PMID:37973913). As a transcriptional co-activator it binds defined promoter motifs and recruits histone acetyltransferases — GCN5 to Smad2/3/4 promoters via its Tudor domain to amplify TGF-β1 signaling (PMID:28263968), GCN5 and CBP/p300 to the SLUG promoter to drive EMT (PMID:30509125), and KAT2B to SRF target genes where it competes with myocardin to promote vascular smooth-muscle proliferation (PMID:38279051); it likewise co-activates HIF1α/EZH2 in tumor-initiating cells (PMID:37622244). As an RNA-binding protein and m6A reader it determines the fate of specific transcripts, stabilizing GPX4 and AT1R mRNAs and m6A-modified viral and Nrf2 RNAs while destabilizing HSPA5, with these activities controlling ferroptosis sensitivity and TGFβ/ERK signaling (PMID:31647415, PMID:24918049, PMID:36453257, PMID:35320827, PMID:37202791). SND1 is most prominently a scaffold for the oncoprotein MTDH: an 11-residue MTDH motif inserts two tryptophan residues into pockets of the SND1 SN1/SN2 groove, and this interaction stabilizes SND1, is required to sustain breast cancer, and forms an MTDH-SND1 complex that destabilizes tumor-suppressor and antigen-presentation mRNAs (Tap1/Tap2, SESN2) (PMID:25242325, PMID:24981741, PMID:35121988, PMID:40775338). SND1 additionally evades immune detection at the ER, where its N-terminus associates with SEC61A and its SN domain diverts nascent MHC-I heavy chain to ERAD (PMID:32917674), and it localizes to mitochondria via an N-terminal targeting sequence to promote PGAM5-dependent mitophagy (PMID:35433434). SND1 activity and abundance are tuned by PIM1/CDK1-driven phosphorylation, USP37-mediated deubiquitination, and N-glycosylation at Asn50 (PMID:40486858, PMID:36213325, PMID:39725102). Genetically, an SND1-BRAF fusion produces a constitutively active MAPK-driving oncoprotein (PMID:22745804), and SND1 is required for dendritic-cell-driven Th1 immunity in vivo (PMID:33635920).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2007 Medium

    Established that SND1 overexpression has oncogenic potential and acts post-transcriptionally, by downregulating APC protein without changing its mRNA and redistributing E-cadherin in intestinal epithelial cells.

    Evidence stable overexpression in IEC6/colon cancer cells with APC protein-vs-mRNA Western blots and proliferation assays

    PMID:17909068

    Open questions at the time
    • mechanism of APC protein loss without mRNA change not resolved
    • RISC component role asserted but not biochemically dissected
  2. 2011 Medium

    Identified SND1 as a physical MTDH partner and a driver of metastasis and chemoresistance, opening the MTDH-SND1 oncogenic axis.

    Evidence mass spectrometry pulldown and Co-IP with knockdown metastasis assays in breast cancer cells

    PMID:21478147

    Open questions at the time
    • interaction interface unknown at this stage
    • downstream mRNA targets of the complex not yet defined
  3. 2012 Medium

    Mapped SND1 into discrete signaling and oncogenic outputs — an NF-κB/miR-221/angiogenic-factor cascade in HCC and a constitutively active SND1-BRAF fusion driving MAPK and inhibitor resistance.

    Evidence gain/loss-of-function with angiogenesis assays and pathway inhibitors; SND1-BRAF fusion expression with ERK readout and inhibitor combinations

    PMID:22396537 PMID:22745804

    Open questions at the time
    • whether SND1 directly activates NF-κB or acts indirectly unresolved
    • SND1-BRAF fusion is a rearrangement-specific event, not general SND1 function
  4. 2012 Medium

    Defined how SND1 expression itself is controlled, showing its promoter is bound and regulated by NF-κB, Sp1 and NF-Y and induced by TNF-α.

    Evidence EMSA, ChIP, luciferase reporters with deletion and site-directed mutagenesis

    PMID:23160072

    Open questions at the time
    • physiological stimuli engaging each factor not fully mapped
  5. 2013 Medium

    Revealed SND1 roles in RNA processing — promoting CD44 alternative splicing via SAM68 and binding/regulating miR-17-92a cluster processing under hypoxia.

    Evidence MS, Co-IP, SAM68 knockdown epistasis and pre-mRNA mutation; RNA pulldown/MS and knockdown miRNA processing assays

    PMID:23770094 PMID:23995791

    Open questions at the time
    • direct RNA-binding determinants on SND1 not defined
    • generality of miRNA processing role beyond hypoxia unknown
  6. 2014 High

    Solved the structural and functional basis of the MTDH-SND1 interaction, showing two MTDH tryptophans dock into SN1/SN2 pockets and that MTDH stabilizes SND1 to sustain tumor-initiating cell survival in vivo.

    Evidence X-ray crystallography with pocket mutagenesis; Co-IP and multiple mouse mammary tumor models

    PMID:24981741 PMID:25242325

    Open questions at the time
    • structure does not define the complex's RNA-degrading active mechanism
    • stabilization mechanism (which ubiquitin machinery is countered) not identified here
  7. 2015 Medium

    Established SND1 as a TGFβ-induced effector and an mRNA-stability regulator, being activated by Smad2/3 and in turn promoting Smurf1-mediated RhoA degradation and stabilizing AT1R mRNA to amplify TGFβ/ERK signaling.

    Evidence promoter ChIP/EMSA, RhoA ubiquitination, mRNA stability assays and metastasis models

    PMID:24918049 PMID:25596283

    Open questions at the time
    • direct SND1 binding to AT1R mRNA not shown
    • feedforward loop with TGFβ not quantified in vivo
  8. 2015 Medium

    Defined SND1 as a chromatin-associated factor on a genome scale, occupying hundreds of promoters and reprogramming glycerolipid gene expression in response to TNFα.

    Evidence ChIP-chip with TNFα stimulation and lipid metabolism knockdown readouts

    PMID:26323317

    Open questions at the time
    • direct vs indirect promoter occupancy not distinguished for all loci
    • co-activator partners at most promoters unidentified
  9. 2017 Medium

    Mechanistically defined SND1 as a Tudor-domain co-activator that recruits GCN5 to Smad2/3/4 promoters and increases H3K9 acetylation, linking its DNA binding to chromatin modification.

    Evidence EMSA, GST pulldown for Tudor requirement, ChIP and phospho-Smad readouts

    PMID:28263968

    Open questions at the time
    • whether Tudor domain reads a histone or protein mark to recruit GCN5 not resolved
  10. 2017 Medium

    Connected SND1 to lipid/metabolic transcriptional control and stress-granule biology, showing SREBP-2 activates and SREBP-1 represses its promoter, and SND1 assembles into microtubule-dependent stress granules under heat shock.

    Evidence ChIP/reporter mutagenesis with SREBP modulation; live-cell imaging with nocodazole disruption

    PMID:28758359 PMID:29296233

    Open questions at the time
    • functional consequence of stress-granule recruitment unknown
    • metabolic feedback between SREBP and SND1 not closed
  11. 2019 Medium

    Broadened the co-activator model to EMT by showing SND1 recruits GCN5 and CBP/p300 to the SLUG promoter, and linked SND1 to PIM1-mediated phosphorylation and senescence.

    Evidence ChIP, co-activator recruitment and invasion assays; LC-MS/MS, Co-IP and senescence (SASP) readouts

    PMID:30509125 PMID:31860636

    Open questions at the time
    • PIM1 phosphorylation site not defined in this study (Low confidence)
    • SLUG co-activation generality across tumor types untested
  12. 2020 High

    Revealed an ER-membrane function for SND1: anchored via SEC61A, its SN domain diverts nascent MHC-I heavy chain to ERAD, providing a direct mechanism for tumor immune evasion.

    Evidence fractionation, Co-IP (SEC61A, MHC-I), ERAD assays and syngeneic mouse tumor models with CD8+ T-cell readout

    PMID:32917674

    Open questions at the time
    • selectivity determinants for MHC-I substrate engagement not defined
    • balance between ER and nuclear pools not quantified
  13. 2021 High

    Validated the MTDH-SND1 interaction as a therapeutic target across breast cancer and immune evasion, showing complex disruption destabilizes Tap1/Tap2 mRNA, enhances antigen presentation, and that small molecules suppress tumor growth.

    Evidence Mtdh genetic ablation mice, PPI small-molecule inhibitors (C26-A2/A6), mRNA stability and T-cell infiltration readouts

    PMID:35121987 PMID:35121988

    Open questions at the time
    • nuclease/destabilization catalytic step within the complex not biochemically isolated
    • full mRNA target spectrum of the complex unmapped
  14. 2021 High

    Established prostate-cancer-specific control of SND1 localization, showing ERG binds the SND1 Tudor domain to drive nuclear localization of the SND1/MTDH complex and growth, and that SND1 supports dendritic-cell Th1 immunity in vivo.

    Evidence domain Co-IP, forced-nuclear-localization experiments, conditional Snd1 knockout prostate model; SND1-KO DC functional and adoptive-transfer assays

    PMID:33635920 PMID:37973913

    Open questions at the time
    • how nuclear vs cytoplasmic partitioning is normally regulated unresolved
    • molecular basis of SND1's DC function not defined
  15. 2022 Medium

    Defined SND1 as a regulator of ferroptosis through opposing mRNA-fate decisions — stabilizing GPX4 to confer cisplatin resistance and destabilizing HSPA5 to promote ferroptosis — and uncovered mitochondrial and glycosylation-dependent functions.

    Evidence 3'UTR binding/luciferase and ferroptosis rescue assays; mitochondrial fractionation/IP-MS with PGAM5; Asn50 glycosylation mutagenesis with ERAD readout

    PMID:35320827 PMID:35433434 PMID:36213325 PMID:36453257

    Open questions at the time
    • context determining stabilization vs destabilization of bound transcripts unknown
    • mitochondrial import and ER/nuclear roles not reconciled into one regulatory logic
  16. 2023 Medium

    Extended SND1's RNA-reader role to viral and stress RNAs and to lncRNA-guided chromatin remodeling, including m6A-dependent Nrf2 regulation, NSP9-dependent SARS-CoV-2 replication, lncTCF7-directed SWI/SNF recruitment, and HIF1α co-activation.

    Evidence RIP/MeRIP/RNA pulldown and rescue; viral RNA binding, Co-IP and covalent-linkage mapping; RNA pulldown/MS and ChIP; PyMT Snd1-KO tumor model

    PMID:37202791 PMID:37622244 PMID:37794589 PMID:39169000

    Open questions at the time
    • whether m6A reading and protein-scaffolding use the same SND1 surface unknown
    • physiological RNA target hierarchy not established
  17. 2024 Medium

    Defined SND1 functions in genome protection and vascular remodeling and refined its post-translational control, including KDM6A-dependent fork protection, ELK1-driven SND1/SRF/KAT2B vascular signaling, and PIM1-S426 phosphorylation strengthening SND1-SMARCA5 chromatin activity.

    Evidence Co-IP and nascent-DNA chromatin analysis; SMC-specific Snd1 KO with wire-injury model, ChIP/Co-IP; PIM1 S426 mutagenesis with Co-IP, ChIP and tumor models

    PMID:38279051 PMID:38850159 PMID:39725102

    Open questions at the time
    • how SND1 partitions between fork protection and transcriptional roles unknown
    • ordering of phosphorylation events relative to partner choice undefined
  18. 2025 Medium

    Integrated SND1 into translational and degradative control loops, showing mTORC1/4E-BP1 represses SND1 translation while SND1 transcriptionally drives a UBE2N DNA-repair program, and that USP37 (CDK1-activated) deubiquitinates and stabilizes SND1, and SREBF1-induced SND1 forms an MTDH complex degrading SESN2 mRNA to activate mTOR.

    Evidence ribosome profiling and mTORC1 modulation with DNA-repair readouts; proteomics, CDK1 T631 site mapping and DUB activity assays; ChIP/RIP-seq with C26-A6 disruption

    PMID:39895626 PMID:40486858 PMID:40775338

    Open questions at the time
    • feedback between SND1-mTOR signaling and its own translational repression not closed
    • in vivo relevance of USP37-SND1 axis beyond CRC untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How SND1 selects between stabilizing versus destabilizing bound mRNAs, and how its activities are partitioned across nuclear chromatin, cytoplasmic RNA, ER membrane, and mitochondria within a single cell, remains unresolved.
  • no unifying biochemical model linking the SN-domain nuclease/scaffold and Tudor reader functions
  • regulatory logic governing subcellular partitioning undefined
  • catalytic step of MTDH-SND1 mRNA degradation not reconstituted

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 4 GO:0060090 molecular adaptor activity 4 GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 3 GO:0042393 histone binding 1
Localization
GO:0005634 nucleus 3 GO:0005783 endoplasmic reticulum 3 GO:0005829 cytosol 2 GO:0005739 mitochondrion 1 GO:0005794 Golgi apparatus 1 GO:0005811 lipid droplet 1
Pathway
R-HSA-1643685 Disease 5 R-HSA-162582 Signal Transduction 4 R-HSA-8953854 Metabolism of RNA 4 R-HSA-168256 Immune System 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1430728 Metabolism 2 R-HSA-73894 DNA Repair 2
Partners
ERGGCN5KDM6AMTDHPGAM5SAM68SEC61ASMARCA5
Complex memberships
MTDH-SND1 complexRISC

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2014 Crystal structure of the MTDH-SND1 complex was determined at high resolution, revealing that an 11-residue MTDH peptide motif occupies an extended groove between SND1's SN1 and SN2 domains, with two MTDH tryptophan residues nestled into two well-defined pockets in SND1. Mutagenesis of both tryptophan-binding pockets disrupted MTDH-SND1 interaction and impaired their roles in breast cancer and SND1 stability under stress. X-ray crystallography, mutagenesis, functional cancer cell assays Cell reports High 25242325
2014 MTDH interacts with and stabilizes SND1; disrupting the MTDH-SND1 interaction (by silencing either protein or disrupting their binding) compromises tumor-initiating cell survival and tumorigenesis in multiple mouse mammary tumor models, establishing that MTDH supports cell survival under oncogenic/stress conditions through SND1 stabilization. Co-immunoprecipitation, mouse genetic tumor models, knockdown/disruption studies with in vivo xenograft/tumor assays Cancer cell High 24981741
2011 SND1 was identified as an MTDH-interacting protein by mass spectrometry-based screen and confirmed by co-immunoprecipitation. SND1 promotes lung metastasis, resistance to apoptosis, and regulates expression of metastasis- and chemoresistance-associated genes in breast cancer cells. Mass spectrometry pulldown, co-immunoprecipitation, loss-of-function (knockdown) with metastasis assays The Journal of biological chemistry Medium 21478147
2019 SND1 functions as an m6A RNA reader: it binds m6A-modified hairpin in KSHV ORF50 RNA, stabilizes the ORF50 transcript, and is essential for KSHV lytic replication. RIP-seq and eCLIP characterization confirmed SND1 as a transcriptome-wide m6A reader. RIP-seq, eCLIP, RNA immunoprecipitation, m6A-modified RNA binding assays, SND1 depletion with viral replication readout eLife High 31647415
2023 SND1 binds the 5' end of SARS-CoV-2 negative-sense viral RNA and is required for viral RNA synthesis. SND1 interacts directly with the viral RNA-binding protein NSP9 and remodels NSP9 occupancy, altering covalent NSP9 linkage to initiating nucleotides at replication-transcription initiation sites. Biochemical fractionation of viral RNA-bound proteins, SND1 depletion with viral RNA synthesis and growth kinetics readout, Co-IP with NSP9, covalent RNA-protein linkage mapping Cell High 37794589
2012 SND1 promotes tumor angiogenesis in hepatocellular carcinoma through a linear pathway: SND1 activates NF-κB, which induces miR-221, which in turn induces angiogenic factors Angiogenin and CXCL16. Inhibition of any component in this cascade blocked SND1-induced angiogenesis. Stable SND1 overexpression/knockdown in HCC cells, CAM assay, HUVEC differentiation assay, reporter and pathway inhibitor experiments The Journal of biological chemistry Medium 22396537
2015 SND1 expression is transcriptionally activated by the TGFβ1/Smad2/Smad3 complex binding to Smad-specific recognition motifs (RD motifs) in the SND1 promoter. SND1 in turn promotes Smurf1 expression, leading to RhoA ubiquitination and degradation, disrupting F-actin organization and increasing breast cancer cell migration, invasion, and metastasis. Promoter analysis (luciferase, EMSA, ChIP), Smad complex gain/loss-of-function, RhoA ubiquitination assay, cell migration/invasion assays, in vivo metastasis models Cancer research Medium 25596283
2017 SND1 directly binds to conserved motifs (motifs 1 and 2) in the promoter regions of Smad2/3/4 genes, recruits the histone acetyltransferase GCN5 through its Tudor domain, increases H3K9 acetylation, and thereby activates Smad2/3/4 transcription to enhance TGFβ1 signaling and breast cancer metastasis. EMSA, GST pulldown (Tudor domain requirement), ChIP, loss-of-function assays, phospho-Smad readout Oncogene Medium 28263968
2013 SND1 interacts with SAM68 (identified by mass spectrometry) and together they promote inclusion of CD44 variable exons in prostate cancer cells. SND1 recruits SAM68 and spliceosomal components to CD44 pre-mRNA; the effect of SND1 on CD44 splicing required SAM68 and intact SAM68-binding sites in the pre-mRNA. Mass spectrometry, co-immunoprecipitation, SAM68 knockdown epistasis, RT-PCR splicing assays, mutation of SAM68-binding sites in pre-mRNA Oncogene Medium 23995791
2016 SND1 interacts with monoglyceride lipase (MGLL), identified by modified yeast two-hybrid and confirmed by co-immunoprecipitation; this interaction results in ubiquitination and proteasomal degradation of MGLL, suppressing its tumor-suppressive function in hepatocellular carcinoma. Yeast two-hybrid, co-immunoprecipitation, ubiquitination assay, MGLL overexpression rescue, in vivo xenograft The Journal of biological chemistry Medium 26997225
2021 The MTDH-SND1 complex suppresses antitumor T cell responses by binding to and destabilizing Tap1/Tap2 mRNAs, reducing antigen presentation machinery components. Pharmacological disruption of the MTDH-SND1 complex with compound C26-A6 enhanced tumor antigen presentation and CD8+ T cell infiltration. Genetic and pharmacological disruption of MTDH-SND1 complex, mRNA stability assays for Tap1/Tap2, in vivo immunological readouts (T cell infiltration, antigen presentation) Nature cancer High 35121988
2021 Genetic ablation of Mtdh in mice inhibits breast cancer development through disruption of the MTDH-SND1 interaction, establishing that the interaction is required to sustain breast cancer progression. Small-molecule inhibitors C26-A2 and C26-A6 disrupting this protein-protein interaction suppressed tumor growth, metastasis, and enhanced chemotherapy sensitivity. Genetically modified mice (Mtdh ablation), small-molecule compound screen against MTDH-SND1 PPI, in vitro and in vivo TNBC preclinical models Nature cancer High 35121987
2020 SND1 is an ER membrane-associated protein: its N-terminal peptide associates with SEC61A anchored on the ER membrane. The SN domain of SND1 catches nascent MHC-I heavy chain and guides it to ER-associated degradation (ERAD), thereby impairing normal MHC-I assembly and antigen presentation, enabling immune evasion by tumor cells. Subcellular fractionation, co-immunoprecipitation (SND1-SEC61A, SND1-MHC-I heavy chain), ERAD pathway assays, SND1 deletion in syngeneic mouse tumor models with CD8+ T cell readout Science advances High 32917674
2022 Mitochondrion-localized SND1 (via N-terminal amino acids 1–63 as a mitochondrial targeting sequence imported via TOM70) interacts with PGAM5 in mitochondria, promoting PGAM5-DRP1 binding and mitophagy, which supports liver cancer cell proliferation and tumor growth. Organelle subcellular isolation, immunoprecipitation-mass spectrometry, domain deletion (MTS mutants), Co-IP, in vitro and in vivo tumor models Frontiers in oncology Medium 35433434
2007 SND1 functions as a component of RISC and overexpression in colon cancer cells causes downregulation of APC protein without altering APC mRNA levels, and alters E-cadherin distribution from membrane to cytoplasm. Stable Snd1 overexpression in IEC6 cells promotes loss of contact inhibition and cell growth. Stable overexpression in intestinal epithelial cells, immunohistochemistry, Western blot (APC protein vs. mRNA), cell proliferation assays Cancer research Medium 17909068
2012 SND1-BRAF chromosomal rearrangement (7q32-7q34) produces a constitutively active SND1-BRAF fusion protein that hyperactivates the MAPK pathway (ERK), conferring resistance to c-Met inhibitor in gastric cancer cells. Combination with RAF or MEK inhibitor overcame resistance. Chromosomal rearrangement characterization, functional expression of SND1-BRAF fusion, ERK phosphorylation assays, inhibitor combination studies PloS one Medium 22745804
2013 SND1 interacts with and regulates processing of miR-17-92a cluster: SND1 binds pre-miR-92a and all mature miR-17-92a members (identified by RNA pulldown and mass spectrometry), and SND1 silencing resolves a hypoxia-induced block in miRNA processing, increasing mature miRNA levels. RNA pulldown, mass spectrometry, SND1 knockdown, miRNA processing Northern/qPCR assays under hypoxic conditions FEBS letters Medium 23770094
2010 SND1 (SND p102) colocalizes with endoplasmic reticulum and Golgi markers by sucrose gradient fractionation, and under steatogenic conditions translocates to and associates specifically with low-density lipid droplets in hepatocytes, as confirmed by both gradient fractionation and confocal microscopy. Sucrose gradient fractionation, confocal microscopy, oleate treatment of HepG2 cells Journal of physiology and biochemistry Medium 20414760
2015 SND1 increases AT1R mRNA stability, resulting in elevated AT1R protein levels, which activates ERK and Smad2 and consequently the TGFβ signaling pathway, promoting EMT, migration, and invasion in hepatocellular carcinoma cells. mRNA stability assays, Western blot for ERK/Smad2 phosphorylation, SND1 overexpression/knockdown, migration/invasion assays FEBS open bio Medium 24918049
2019 SND1 acts upstream of SLUG to promote EMT: SND1 recruits acetyltransferases GCN5 and CBP/p300 to the SLUG promoter, increasing chromatin accessibility and activating SLUG transcription; SLUG then regulates N-CAD, VIM, E-CAD, and CLDN1 expression to promote EMT in ovarian cancer cells. ChIP, gene expression profiling, SND1 loss-of-function, co-activator recruitment assays, invasion/migration assays FASEB journal Medium 30509125
2012 The SND1 gene promoter is regulated by NF-κB, Sp1, and NF-Y transcription factors. EMSA and ChIP confirmed direct binding of these factors to specific sites in the SND1 proximal promoter; mutation of CCAAT/GC boxes and NF-κB elements substantially reduced SND1 promoter activity. TNF-α-induced upregulation of SND1 is mediated at least in part via NF-κB. EMSA, ChIP, luciferase reporter assays with deletion analysis and site-directed mutagenesis Biochimie Medium 23160072
2015 SND1 occupies 645 gene promoters in HepG2 cells under basal conditions and 281 additional promoters upon TNFα treatment, as determined by ChIP-chip. SND1 deficiency compromises glycerolipid gene reprogramming and lipid phenotypic responses to TNFα. ChIP-chip, transcription factor binding site analysis, SND1 knockdown with lipid metabolism readout Nucleic acids research Medium 26323317
2017 SREBP-2 directly binds to SRE and E-box motifs in the SND1 proximal promoter to activate SND1 transcription, as shown by ChIP and site-directed mutagenesis. SREBP-1c/1a binds the SRE element and represses SND1 transcription. SREBP-2 activating conditions (simvastatin, lipoprotein-deficient medium) increase SND1 mRNA and promoter activity. ChIP, luciferase reporter assays, site-directed mutagenesis, SREBP overexpression and siRNA knockdown Oncotarget Medium 29296233
2017 SND1 localizes to stress granules under heat shock, and this recruitment requires intact microtubule cytoskeleton tracks; nocodazole-mediated microtubule depolymerization significantly impairs SND1 granule assembly during heat shock. SND1 granules co-localize with α-tubulin microtubules. Immunofluorescence live-cell imaging, nocodazole treatment, heat shock assay, co-localization analysis Anatomical record Medium 28758359
2019 PIM1 kinase directly binds and phosphorylates SND1; decreased SND1 expression leads to upregulation of senescence-associated secretory phenotype (SASP), and SND1 is involved in PIM1-mediated cellular senescence. Silver staining/LC-MS/MS identification of PIM1-interacting proteins, Co-IP, immunofluorescence, Western blot, cell proliferation assays Medical science monitor Low 31860636
2021 SND1 Tudor domain interacts with ERG (an ETS-domain transcription factor overexpressed in prostate cancer); ERG promotes nuclear localization of the SND1/MTDH complex; forced nuclear localization of SND1 prominently increases its growth-promoting function; prostate-specific Snd1 deletion reduces cancer growth in PB-Cre/Ptenflox/flox/ERG mice. Co-immunoprecipitation (Tudor domain), domain-specific interaction mapping, nuclear localization forced-expression experiments, Snd1 conditional knockout mouse prostate cancer model Nature communications High 37973913
2022 SND1 binds to the 3' UTR of GPX4 mRNA and stabilizes it; knockdown of SND1 in bladder cancer cells promotes ferroptosis by destabilizing GPX4 mRNA, overcoming cisplatin resistance. ChIP and dual-luciferase assay for SND1-GPX4 mRNA 3'UTR binding, RNA interference, ferroptosis assays (ROS, iron, GSH, MDA), GPX4 overexpression rescue Oncology reports Medium 36453257
2022 SND1 destabilizes HSPA5 mRNA by binding to its 3'UTR, leading to reduced HSPA5 protein, which in turn reduces GPX4 expression (since HSPA5 protein directly stabilizes GPX4), ultimately promoting ferroptosis in osteoarthritis chondrocytes. RNA binding (3'UTR binding assay), mRNA stability assay, Co-IP for HSPA5-GPX4 interaction, SND1 knockdown in vivo (rat OA model), IL-1β-stimulated chondrocyte model Inflammation research Medium 35320827
2024 KDM6A interacts with SND1 (interaction enhanced by KDM6A SUMOylation at K90); the KDM6A-SND1 complex protects nascent DNA by recruiting RPA and Ku70, preventing replication fork collapse. Loss of KDM6A or SND1 increases H3K9ac and H4K8ac but attenuates Ku70 and H3K4me3 at nascent DNA, enhancing genotoxin sensitivity. Co-IP, nascent DNA chromatin analysis (Ku70/RPA enrichment), histone modification ChIP, KDM6A mutation analysis, genotoxin sensitivity assays Nucleic acids research Medium 38850159
2024 In vascular smooth muscle cells, ELK1 transcription factor binds the Snd1 promoter to activate its transcription upon PDGF stimulation. Upregulated SND1 then competes with myocardin for SRF binding and recruits KAT2B (histone acetyltransferase) to SRF target gene promoters, increasing histone acetylation and promoting SRF-driven transcription of proliferation- and migration-related genes, thereby inducing neointimal hyperplasia. SMC-specific Snd1 knockout mice showed reduced neointimal hyperplasia. ChIP, Co-IP (SND1-SRF interaction), chromatin accessibility/histone acetylation assays, SMC-specific conditional Snd1 knockout mice, wire-injury vascular model Cellular and molecular life sciences High 38279051
2025 SND1 translational repression is mediated by the mTORC1/4E-BP1 pathway under sunitinib stress in endothelial cells. SND1 transcriptionally regulates UBE2N, an E2-conjugating enzyme mediating K63-linked ubiquitination; UBE2N, together with E3 ligases RNF8 and RNF168, mediates the DNA damage repair response that protects endothelial cells from sunitinib-induced dysfunction. Ribosome profiling (translational control mapping), mTORC1/4E-BP1 pathway modulation, SND1 OE/knockdown, UBE2N downstream identification, DNA damage repair assays, in vitro and in vivo vascular dysfunction models The Journal of clinical investigation Medium 39895626
2023 SND1 binds to and stabilizes lncTCF7, and together SND1 and lncTCF7 are required for recruitment of the SWI/SNF chromatin remodeling complex to the TCF7 promoter to activate TCF7 transcription. The SND1-binding region maps to the 3'-end of lncTCF7. RNA pulldown, quantitative mass spectrometry, knockdown epistasis, ChIP (SND1, SWI/SNF recruitment), structural probing of lncTCF7 subdomains Scientific reports Medium 39169000
2025 USP37 is the deubiquitinase of SND1, stabilizing SND1 protein. CDK1 phosphorylates USP37 at threonine 631 (not serine 628), enhancing USP37 deubiquitinase activity and thereby stabilizing SND1 to drive colorectal cancer progression. Dacarbazine was identified as a pharmacological inhibitor of USP37 that disrupts SND1 stability. Proteomics, ubiquitinomics, interactomics (MS-based), CDK1 phosphorylation site mapping (T631 vs S628 mutagenesis), USP37 deubiquitinase activity assay, in vivo CRC models Acta pharmaceutica sinica. B Medium 40486858
2021 SPT6 interacts with SND1 to co-activate hTERT expression and promote colon cancer cell proliferation, stemness, and growth in vitro and in vivo. SPT6 was identified by pull-down/mass spectrometry as a protein binding the hTERT promoter. Pulldown/mass spectrometry, SPT6-SND1 interaction confirmed, hTERT promoter reporter assays, in vitro and xenograft in vivo models Molecular oncology Low 33305480
2023 SNAI3-AS1 competitively binds SND1 and perturbs m6A-dependent recognition of Nrf2 mRNA 3'UTR by SND1, reducing Nrf2 mRNA stability and sensitizing glioma cells to ferroptosis. RNA pulldown, RIP, MeRIP, dual-luciferase reporter assay, gain/loss-of-function rescue experiments Journal of experimental & clinical cancer research Medium 37202791
2023 SND1 co-activates HIF1α as a transcriptional co-activator, regulating downstream EZH2 transcription, and thereby promotes PyMT-induced breast tumor initiation and expansion of tumor-initiating cells. SND1 knockout in PyMT mouse model, histological and cytometric analysis, mechanistic co-activator assays (SND1-HIF1α interaction and EZH2 transcription readout) The FEBS journal Medium 37622244
2022 N-glycosylation of SND1 at Asn50 is required for its folding and stability; mutation of Asn50 destabilizes SND1 and leads to its ER-associated degradation, inhibiting glioma cell proliferation and metastasis. Site-directed mutagenesis of four N-glycosylation sites (N50, N168, N283, N416), Western blot, ERAD pathway assays, cell proliferation and invasion assays Journal of immunology research Medium 36213325
2024 PIM1-catalyzed phosphorylation of SND1 at serine 426 strengthens SND1-SMARCA5 interaction; this interaction mediates SND1's regulation of chromatin dynamics and transcriptional activation of CUX1 oncogene, promoting ESCC progression. Disruption of S426 phosphorylation impaired SND1-SMARCA5 interaction and inhibited ESCC tumor growth in vivo. PIM1 phosphorylation assay (S426 site-directed mutagenesis), Co-IP (SND1-SMARCA5), ChIP (histone modification, RNA polymerase II), in vivo tumor models International journal of biological macromolecules Medium 39725102
2025 SREBF1 binds the SND1 gene promoter and activates its transcription; SND1 then forms a complex with MTDH that directly binds and degrades SESN2 mRNA, activating mTOR signaling and promoting prostate cancer progression. Disruption of the MTDH-SND1 interaction with C26-A6 inhibited SESN2 mRNA degradation. ChIP, dual-luciferase reporter assay, DNA pulldown, RIP-seq and RNA pulldown (SESN2 mRNA binding), pharmacological disruption (C26-A6), in vitro and xenograft models Journal of translational medicine Medium 40775338
2021 In SND1 knockout mice, dendritic cells show lower costimulatory molecule expression and IL-12 production and higher IL-10 production; adoptive transfer of SND1-KO DCs failed to protect against chlamydial challenge infection and showed reduced ability to promote Th1 responses. This establishes SND1 as required for normal DC function in promoting Th1/17 immunity. SND1 knockout mouse model, DC isolation and functional assays, DC-T cell co-culture, adoptive DC transfer, in vivo chlamydial lung infection model PLoS pathogens Medium 33635920
2023 The SN domain of SND1 interacts with MHC-I heavy chain at K490-containing sites (as determined by structure-based virtual screening and docking analysis); EGC (-)-Epigallocatechin prevents SND1-MHC-I binding by altering the spatial conformation of SND1 at this site, restoring MHC-I surface presentation and CD8+ T cell responses. Structure-based virtual screening, molecular docking, EGC treatment with MHC-I surface expression readout, in vivo melanoma mouse model, CD8+ T cell functional assays Cancer letters Low 38710299

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics 125 32645525
2012 Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. The Journal of biological chemistry 123 22396537
2012 Splice variant of the SND1 transcription factor is a dominant negative of SND1 members and their regulation in Populus trichocarpa. Proceedings of the National Academy of Sciences of the United States of America 121 22915581
2014 MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors. Cancer cell 119 24981741
2019 The Tudor SND1 protein is an m6A RNA reader essential for replication of Kaposi's sarcoma-associated herpesvirus. eLife 111 31647415
2013 SND1 transcription factor-directed quantitative functional hierarchical genetic regulatory network in wood formation in Populus trichocarpa. The Plant cell 108 24280390
2011 Identification of staphylococcal nuclease domain-containing 1 (SND1) as a Metadherin-interacting protein with metastasis-promoting functions. The Journal of biological chemistry 106 21478147
2007 SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer research 102 17909068
2015 SND1 Acts Downstream of TGFβ1 and Upstream of Smurf1 to Promote Breast Cancer Metastasis. Cancer research 86 25596283
2013 The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene 81 23995791
2014 Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness. Neuro-oncology 71 25216670
2022 The RNA-binding protein SND1 promotes the degradation of GPX4 by destabilizing the HSPA5 mRNA and suppressing HSPA5 expression, promoting ferroptosis in osteoarthritis chondrocytes. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 63 35320827
2021 Pharmacological disruption of the MTDH-SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nature cancer 61 35121988
2021 Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasis. Nature cancer 57 35121987
2020 Oncoprotein SND1 hijacks nascent MHC-I heavy chain to ER-associated degradation, leading to impaired CD8+ T cell response in tumor. Science advances 48 32917674
2017 SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFβ1 response and breast cancer metastasis. Oncogene 47 28263968
2012 A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PloS one 46 22745804
2023 Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1. Journal of experimental & clinical cancer research : CR 45 37202791
2014 Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. FEBS open bio 45 24918049
2014 Structural insights into the tumor-promoting function of the MTDH-SND1 complex. Cell reports 43 25242325
2018 SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. RNA biology 42 30321081
2020 LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SND1 Axis. OncoTargets and therapy 40 32273723
2022 Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. Journal of experimental & clinical cancer research : CR 39 35659274
2018 Insights Into SND1 Oncogene Promoter Regulation. Frontiers in oncology 36 30619748
2016 Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL). The Journal of biological chemistry 36 26997225
2015 Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers. Scientific reports 36 25985019
2010 MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutation research 34 20883704
2023 SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis through NSP9. Cell 33 37794589
2018 SND1 acts upstream of SLUG to regulate the epithelial-mesenchymal transition (EMT) in SKOV3 cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 31 30509125
2019 PTB-AS, a Novel Natural Antisense Transcript, Promotes Glioma Progression by Improving PTBP1 mRNA Stability with SND1. Molecular therapy : the journal of the American Society of Gene Therapy 30 31253583
2022 LncRNA SND1-IT1 facilitates TGF-β1-induced epithelial-to-mesenchymal transition via miR-124/COL4A1 axis in gastric cancer. Cell death discovery 26 35184134
2021 Circ SMARCA5 Inhibited Tumor Metastasis by Interacting with SND1 and Downregulating the YWHAB Gene in Cervical Cancer. Cell transplantation 26 33588586
2019 SND1 facilitates the invasion and migration of cervical cancer cells by Smurf1-mediated degradation of FOXA2. Experimental cell research 26 31891682
2020 MTDH promotes metastasis of clear cell renal cell carcinoma by activating SND1-mediated ERK signaling and epithelial-mesenchymal transition. Aging 24 31978894
2018 miR-361-5p inhibits glioma migration and invasion by targeting SND1. OncoTargets and therapy 24 30214229
2015 Profiling of promoter occupancy by the SND1 transcriptional coactivator identifies downstream glycerolipid metabolic genes involved in TNFα response in human hepatoma cells. Nucleic acids research 24 26323317
2010 Association of SND1 protein to low density lipid droplets in liver steatosis. Journal of physiology and biochemistry 24 20414760
2023 Circular RNA METTL9 contributes to neuroinflammation following traumatic brain injury by complexing with astrocytic SND1. Journal of neuroinflammation 22 36803376
2022 Mitochondrion-Localized SND1 Promotes Mitophagy and Liver Cancer Progression Through PGAM5. Frontiers in oncology 22 35433434
2022 Exosome-mediated lncRNA SND1-IT1 from gastric cancer cells enhances malignant transformation of gastric mucosa cells via up-regulating SNAIL1. Journal of translational medicine 22 35739527
2019 LncRNA SND1-IT1 accelerates the proliferation and migration of osteosarcoma via sponging miRNA-665 to upregulate POU2F1. European review for medical and pharmacological sciences 22 31799644
2013 SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. Anatomical record (Hoboken, N.J. : 2007) 22 23878061
2012 NF-κB, Sp1 and NF-Y as transcriptional regulators of human SND1 gene. Biochimie 22 23160072
2023 ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association. Discover oncology 20 37147528
2022 Cleavage of tropomodulin-3 by asparagine endopeptidase promotes cancer malignancy by actin remodeling and SND1/RhoA signaling. Journal of experimental & clinical cancer research : CR 20 35765111
2020 miR-1224-5p inhibits the proliferation and invasion of ovarian cancer via targeting SND1. Human cell 20 32409958
2013 Regulation of miR-17-92a cluster processing by the microRNA binding protein SND1. FEBS letters 20 23770094
2017 SREBP-2-driven transcriptional activation of human SND1 oncogene. Oncotarget 19 29296233
2023 SND1 binds to ERG and promotes tumor growth in genetic mouse models of prostate cancer. Nature communications 18 37973913
2020 Molecular and cellular insights into the role of SND1 in lipid metabolism. Biochimica et biophysica acta. Molecular and cell biology of lipids 18 31978555
2020 Linc00668 Promotes Invasion and Stem Cell-Like Properties of Breast Cancer Cells by Interaction With SND1. Frontiers in oncology 18 32117742
2023 Molecular Dynamics Simulation-Driven Focused Virtual Screening and Experimental Validation of Inhibitors for MTDH-SND1 Protein-Protein Interaction. Journal of chemical information and modeling 17 37226724
2022 Inhibition of SND1 overcomes chemoresistance in bladder cancer cells by promoting ferroptosis. Oncology reports 17 36453257
2018 SND1 promotes the proliferation of osteosarcoma cells by upregulating COX‑2/PGE2 expression via activation of NF‑κB. Oncology reports 17 30365124
2018 The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. Hepatoma research 17 32258418
2024 Vascular injury activates the ELK1/SND1/SRF pathway to promote vascular smooth muscle cell proliferative phenotype and neointimal hyperplasia. Cellular and molecular life sciences : CMLS 16 38279051
2023 The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation. Breast cancer research : BCR 15 37885030
2022 Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction. Journal of medicinal chemistry 15 36044768
2021 The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma. Epigenomes 15 33768972
2016 Correlated overexpression of metadherin and SND1 in glioma cells. Biological chemistry 15 26351803
2020 Disruption of SND1-MTDH Interaction by a High Affinity Peptide Results in SND1 Degradation and Cytotoxicity to Breast Cancer Cells In Vitro and In Vivo. Molecular cancer therapeutics 14 33268570
2016 SND1 overexpression deregulates cholesterol homeostasis in hepatocellular carcinoma. Biochimica et biophysica acta 14 27238764
2023 SNHG1, interacting with SND1, contributes to sorafenib resistance of liver cancer cells by increasing m6A-mediated SLC7A11 expression and promoting aerobic glycolysis. Environmental toxicology 13 37927237
2021 SPT6 recruits SND1 to co-activate human telomerase reverse transcriptase to promote colon cancer progression. Molecular oncology 13 33305480
2014 The promoter of cell growth- and RNA protection-associated SND1 gene is activated by endoplasmic reticulum stress in human hepatoma cells. BMC biochemistry 13 25494629
2024 KDM6A-SND1 interaction maintains genomic stability by protecting the nascent DNA and contributes to cancer chemoresistance. Nucleic acids research 12 38850159
2018 Channeling of newly synthesized fatty acids to cholesterol esterification limits triglyceride synthesis in SND1-overexpressing hepatoma cells. Biochimica et biophysica acta. Molecular and cell biology of lipids 12 30448348
2024 EGC enhances tumor antigen presentation and CD8+ T cell-mediated antitumor immunity via targeting oncoprotein SND1. Cancer letters 11 38710299
2021 PAX5 activates telomerase activity and proliferation in keloid fibroblasts by transcriptional regulation of SND1, thus promoting keloid growth in burn-injured skin. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 11 33616676
2021 SND1 promotes Th1/17 immunity against chlamydial lung infection through enhancing dendritic cell function. PLoS pathogens 11 33635920
2019 LincRNA TINCR facilitates excessive proliferation and inflammation in post-burn skin fibroblasts by directly binding with SND1 protein and inducing SND1-mediated TGF-β1 expression. Biochemical and biophysical research communications 11 30642630
2017 Aggregation of SND1 in Stress Granules is Associated with the Microtubule Cytoskeleton During Heat Shock Stimulus. Anatomical record (Hoboken, N.J. : 2007) 11 28758359
2021 Long non-coding RNA SND1-IT1 accelerates cell proliferation, invasion and migration via regulating miR-132-3p/SMAD2 axis in retinoblastoma. Bioengineered 10 34969359
2025 Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction. Journal of medicinal chemistry 9 39792778
2023 Intracellular Delivery of Stabilized Peptide Blocking MTDH-SND1 Interaction for Breast Cancer Suppression. JACS Au 9 38274259
2021 miRNA-296-5p functions as a potential tumor suppressor in human osteosarcoma by targeting SND1. Chinese medical journal 9 33652459
2014 Tipping the balance: MTDH-SND1 curbs oncogene-induced apoptosis and promotes tumorigenesis. Cell stem cell 9 25105576
2023 SND1, a novel co-activator of HIF1α, promotes tumor initiation in PyMT-induced breast tumor. The FEBS journal 8 37622244
2022 RNA-sequencing of myxoinflammatory fibroblastic sarcomas reveals a novel SND1::BRAF fusion and 3 different molecular aberrations with the potential to upregulate the TEAD1 gene including SEC23IP::VGLL3 and TEAD1::MRTFB gene fusions. Virchows Archiv : an international journal of pathology 8 35776191
2022 Inhibition of RNA Binding in SND1 Increases the Levels of miR-1-3p and Sensitizes Cancer Cells to Navitoclax. Cancers 8 35804872
2023 LncRNA LNC-565686 Promotes Proliferation of Prostate Cancer by Inhibiting Apoptosis through Stabilizing SND1. Biomedicines 7 37893001
2022 SND1 Promotes Radioresistance in Cervical Cancer Cells by Targeting the DNA Damage Response. Cancer biotherapy & radiopharmaceuticals 7 35271349
2022 SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells. Medical oncology (Northwood, London, England) 7 35972612
2025 CDK1-mediated phosphorylation of USP37 regulates SND1 stability and promotes oncogenesis in colorectal cancer. Acta pharmaceutica Sinica. B 6 40486858
2023 Exploring binding modes of the selected inhibitors to SND1 by all-atom molecular dynamics simulations. Journal of biomolecular structure & dynamics 6 37345536
2024 A novel partnership between lncTCF7 and SND1 regulates the expression of the TCF7 gene via recruitment of the SWI/SNF complex. Scientific reports 5 39169000
2022 SND1 acts as a functional target of miR-330-5p involved in modulating the proliferation, apoptosis and invasion of colorectal cancer cells. Biochemical and biophysical research communications 5 35609416
2022 lncRNA SND1-IT1 delivered via intracerebral hemorrhage-derived exosomes affect the growth of human microglia by regulating the miR-124-3p/MTF1 axis. Journal of cellular physiology 5 36548450
2019 The Oncogene PIM1 Contributes to Cellular Senescence by Phosphorylating Staphylococcal Nuclease Domain-Containing Protein 1 (SND1). Medical science monitor : international medical journal of experimental and clinical research 5 31860636
2025 The crosstalk between SND1 and PDCD4 is associated with chemoresistance of non-small cell lung carcinoma cells. Cell death discovery 4 39885142
2025 Oncoprotein SND1-enriched exosomes facilitate melanoma lung metastasis by regulating CD47-SIRPα-mediated macrophage reprogramming. Cancer letters 4 41015268
2024 SND1-SMARCA5 interaction strengthened by PIM promotes the proliferation, metastasis, and chemoresistance of esophageal squamous cell carcinoma. International journal of biological macromolecules 4 39725102
2022 N-Glycosylation on Asn50 of SND1 Is Required for Glioma U87 Cell Proliferation and Metastasis. Journal of immunology research 4 36213325
2021 Impact of hepatocyte-specific deletion of staphylococcal nuclease and tudor domain containing 1 (SND1) on liver insulin resistance and acute liver failure of mice. Bioengineered 4 34608846
2019 Protective effects of SND1 in retinal photoreceptor cell damage induced by ionizing radiation. Biochemical and biophysical research communications 4 31084926
2024 Hypomethylation-associated LINC00987 downregulation induced lung adenocarcinoma progression by inhibiting the phosphorylation-mediated degradation of SND1. Molecular carcinogenesis 3 38607240
2023 Cheminformatics and biomolecular dynamics studies towards the discovery of anti-staphylococcal nuclease domain-containing 1 (SND1) inhibitors to treat metastatic breast cancer. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society 3 37693734
2023 SND1 aggravates mitochondrial damage, apoptosis and extracellular matrix degradation in IL-1β-stimulated chondrocytes via PINK1/BECN1 pathway. European journal of medical research 3 37749650
2025 Translational regulation of SND1 governs endothelial homeostasis during stress. The Journal of clinical investigation 2 39895626
2025 SREBF1-mediated SND1 transcriptional activation promotes prostate cancer progression via MTDH interaction through the SESN2/AMPK/mTOR axis. Journal of translational medicine 2 40775338

Missed literature

Know a paper Affinage missed for SND1? Flag it for the maintainers and the community.

No submissions yet.